RxDoctor Payments DataLook up a doctor →

James Ewing, MD

Medical Oncology · Glendale, AZNPI 1689837601

Payments from drug & device makers

$42,005in general payments, 2019–2025

Across 717 payments — averaging $58.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$8K
  • AstraZeneca$5K
  • Incyte Corporation$5K
  • Geron Corporation$4K
  • Novartis$2K
  • Exelixis Inc.$2K
  • plus $16K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb25$8,472
AstraZeneca(2 entities)32$5,048
Incyte Corporation17$4,502
Geron Corporation9$3,715
Novartis49$2,402
Exelixis Inc.8$2,130
Beigene USA, Inc.3$1,992
Gilead(2 entities)11$1,194
Beigene, Ltd.2$975
Pfizer65$926
Amgen49$886
AbbVie50$882
E.r. Squibb & Sons, L.L.C.47$854
Merck37$831
EMD Serono, Inc.8$714
Johnson & Johnson(2 entities)24$485
Sanofi26$478
GSK23$413
Genentech USA, Inc.19$398
Array Biopharma Inc24$363
Astellas Pharma US Inc13$288
Lilly USA, LLC13$279
Eisai Inc.11$261
Daiichi Sankyo Inc.10$259
Pharmacyclics LLC, An Abbvie Company12$255
Seagen Inc.14$244
Bayer11$198
Inari Medical, Inc.1$194
Servier Pharmaceuticals LLC9$189
Adaptive Biotechnologies Corporation3$163
Takeda Pharmaceuticals U.S.A., Inc.6$161
Rigel Pharmaceuticals, Inc.9$159
Secura Bio, Inc.3$129
Jazz Pharmaceuticals Inc.5$127
Blueprint Medicines Corporation6$122
Genmab U.S., Inc.4$100
Ipsen Biopharmaceuticals, Inc5$99
Kyowa Kirin, Inc.5$93
Tersera Therapeutics LLC3$82
CTI Biopharma Corp.3$76
Puma Biotechnology, Inc.3$71
Boehringer Ingelheim3$67
Sun Pharmaceutical Industries Inc.4$63
Stemline Therapeutics Inc.2$51
AVEO Pharmaceuticals, Inc.3$50
Mirati Therapeutics, Inc.3$47
Karyopharm Therapeutics Inc.3$47
Kerecis Limited1$45
Springworks Therapeutics, Inc.2$44
Agios Pharmaceuticals, Inc.1$44
Progenics Pharmaceuticals, Inc.2$41
AMAG Pharmaceuticals, Inc.2$39
Epizyme, Inc.2$38
Sumitomo Pharma America, Inc.1$25
Sobi, Inc1$22
Organon1$22
Pharmaessentia USA Corporation1$21
CSL Behring1$20
G1 Therapeutics, Inc.1$18
Morphosys, US Inc.1$18

How this compares

$42,005 in reported general payments places this provider in the 50th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$4,361,422
Medicare patients
565
Services billed
176,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →